Phathom Pharmaceuticals

General Information


We are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our initial product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker, or P-CAB. P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over standard of care treatments as a single agent in the treatment of gastroesophageal reflux disease, or GERD, and in combination with antibiotics for the treatment of Helicobacter pylori, or H. pylori, infection.

Employees: 16
Founded: 2018
Contact Information
Address 2150 E. Lake Cook Road, Suite 800, Buffalo Grove, IL 60089, US
Phone Number 650-325-5156
Web Address
View Prospectus: Phathom Pharmaceuticals
Financial Information
Market Cap $523.4mil
Revenues $0 mil (last 12 months)
Net Income $-89.8 mil (last 12 months)
IPO Profile
Symbol PHAT
Exchange NASDAQ
Shares (millions): 9.6
Price range $19.00 - $19.00
Est. $ Volume $182.4 mil
Manager / Joint Managers Goldman Sachs/ Jefferies/ Evercore
CO-Managers Needham & Co.
Expected To Trade: 10/25/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change